01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
Au cours des dernières années, nous avons constaté qu’un bon nombre d’opérations de fusion et acqu...
Read More >
On January 28, 2020, the Federal Trade Commission (FTC) announced its annual increase of the jurisdi...
Read More >
USCIS has confirmed they will open the new H-1B Lottery pre-registration portal on March 1, 2020. Th...
Read More >
WHAT HAPPENED: • On September 4, 2019, the US Department of Justice’s Antitrust Division (DOJ) su...
Read More >
ERISA Section 206(d)(3)(G)(ii) requires sponsors of qualified retirement plans to maintain written p...
Read More >
The parties to class action litigation frequently contest whether plaintiffs are entitled to pre-cer...
Read More >